BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 30894200)

  • 21. Benefit of re-operation and salvage therapies for recurrent glioblastoma multiforme: results from a single institution.
    Azoulay M; Santos F; Shenouda G; Petrecca K; Oweida A; Guiot MC; Owen S; Panet-Raymond V; Souhami L; Abdulkarim BS
    J Neurooncol; 2017 May; 132(3):419-426. PubMed ID: 28374095
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multi-omics analysis of primary glioblastoma cell lines shows recapitulation of pivotal molecular features of parental tumors.
    Rosenberg S; Verreault M; Schmitt C; Guegan J; Guehennec J; Levasseur C; Marie Y; Bielle F; Mokhtari K; Hoang-Xuan K; Ligon K; Sanson M; Delattre JY; Idbaih A
    Neuro Oncol; 2017 Feb; 19(2):219-228. PubMed ID: 27571888
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genetic, Epigenetic, and Immunologic Profiling of MMR-Deficient Relapsed Glioblastoma.
    Indraccolo S; Lombardi G; Fassan M; Pasqualini L; Giunco S; Marcato R; Gasparini A; Candiotto C; Nalio S; Fiduccia P; Fanelli GN; Pambuku A; Della Puppa A; D'Avella D; Bonaldi L; Gardiman MP; Bertorelle R; De Rossi A; Zagonel V
    Clin Cancer Res; 2019 Mar; 25(6):1828-1837. PubMed ID: 30514778
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression pattern and prognostic significance of myosin light chain 9 (MYL9): a novel biomarker in glioblastoma.
    Kruthika BS; Sugur H; Nandaki K; Arimappamagan A; Paturu K; Santosh V
    J Clin Pathol; 2019 Oct; 72(10):677-681. PubMed ID: 31270134
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epidermal Growth Factor Receptor Expression Predicts Time and Patterns of Recurrence in Patients with Glioblastoma After Radiotherapy and Temozolomide.
    Tini P; Nardone V; Pastina P; Battaglia G; Miracco C; Carbone SF; Sebaste L; Rubino G; Cerase A; Pirtoli L
    World Neurosurg; 2018 Jan; 109():e662-e668. PubMed ID: 29061455
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular Targets and Nanoparticulate Systems Designed for the Improved Therapeutic Intervention in Glioblastoma Multiforme.
    Akhter MH; Rizwanullah M; Ahmad J; Amin S; Ahmad MZ; Minhaj MA; Mujtaba MA; Ali J
    Drug Res (Stuttg); 2021 Mar; 71(3):122-137. PubMed ID: 33167048
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Glioblastoma: Overview of Disease and Treatment.
    Davis ME
    Clin J Oncol Nurs; 2016 Oct; 20(5 Suppl):S2-8. PubMed ID: 27668386
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Radiologic progression of glioblastoma under therapy-an exploratory analysis of AVAglio.
    Nowosielski M; Ellingson BM; Chinot OL; Garcia J; Revil C; Radbruch A; Nishikawa R; Mason WP; Henriksson R; Saran F; Kickingereder P; Platten M; Sandmann T; Abrey LE; Cloughesy TF; Bendszus M; Wick W
    Neuro Oncol; 2018 Mar; 20(4):557-566. PubMed ID: 29016943
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Glucocorticoids promote a glioma stem cell-like phenotype and resistance to chemotherapy in human glioblastoma primary cells: Biological and prognostic significance.
    Kostopoulou ON; Mohammad AA; Bartek J; Winter J; Jung M; Stragliotto G; Söderberg-Nauclér C; Landázuri N
    Int J Cancer; 2018 Mar; 142(6):1266-1276. PubMed ID: 29067692
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nivolumab for patients with recurrent glioblastoma progressing on bevacizumab: a retrospective case series.
    Chamberlain MC; Kim BT
    J Neurooncol; 2017 Jul; 133(3):561-569. PubMed ID: 28500559
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comprehensive portrait of recurrent glioblastoma multiforme in molecular and clinical characteristics.
    Li R; Chen X; You Y; Wang X; Liu Y; Hu Q; Yan W
    Oncotarget; 2015 Oct; 6(31):30968-74. PubMed ID: 26427041
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Single-agent Bevacizumab in Recurrent Glioblastoma After Second-line Chemotherapy With Fotemustine: The Experience of the Italian Association of Neuro-Oncology.
    Pasqualetti F; Pace A; Gonnelli A; Villani V; Cantarella M; Delishaj D; Vivaldi C; Molinari A; Montrone S; Pellerino A; Franchino F; Baldaccini D; Lombardi G; Lolli I; Catania F; Bazzoli E; Morganti R; Fabi A; Zagonel V; Bocci G; Fabrini MG; Rudà R; Soffietti R; Paiar F
    Am J Clin Oncol; 2018 Dec; 41(12):1272-1275. PubMed ID: 29782366
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epidermal Growth Factor Receptor Variant III (EGFRvIII) Positivity in
    Felsberg J; Hentschel B; Kaulich K; Gramatzki D; Zacher A; Malzkorn B; Kamp M; Sabel M; Simon M; Westphal M; Schackert G; Tonn JC; Pietsch T; von Deimling A; Loeffler M; Reifenberger G; Weller M;
    Clin Cancer Res; 2017 Nov; 23(22):6846-6855. PubMed ID: 28855349
    [No Abstract]   [Full Text] [Related]  

  • 34. ATP binding cassette (ABC) transporters: expression and clinical value in glioblastoma.
    Dréan A; Rosenberg S; Lejeune FX; Goli L; Nadaradjane AA; Guehennec J; Schmitt C; Verreault M; Bielle F; Mokhtari K; Sanson M; Carpentier A; Delattre JY; Idbaih A
    J Neurooncol; 2018 Jul; 138(3):479-486. PubMed ID: 29520610
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy.
    Nguyen HN; Lie A; Li T; Chowdhury R; Liu F; Ozer B; Wei B; Green RM; Ellingson BM; Wang HJ; Elashoff R; Liau LM; Yong WH; Nghiemphu PL; Cloughesy T; Lai A
    Neuro Oncol; 2017 Mar; 19(3):394-404. PubMed ID: 27571882
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical practice experience with NovoTTF-100A™ system for glioblastoma: The Patient Registry Dataset (PRiDe).
    Mrugala MM; Engelhard HH; Dinh Tran D; Kew Y; Cavaliere R; Villano JL; Annenelie Bota D; Rudnick J; Love Sumrall A; Zhu JJ; Butowski N
    Semin Oncol; 2014 Oct; 41 Suppl 6():S4-S13. PubMed ID: 25213869
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of Concomitant Radiochemotherapy on Invasion Potential of Glioblastoma.
    Hutóczki G; Bognár L; Tóth J; Scholtz B; Zahuczky G; Hanzély Z; Csősz É; Reményi-Puskár J; Kalló G; Hortobágyi T; Klekner A
    Pathol Oncol Res; 2016 Jan; 22(1):155-60. PubMed ID: 26450124
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Response patterns of recurrent glioblastomas treated with tumor-treating fields.
    Vymazal J; Wong ET
    Semin Oncol; 2014 Oct; 41 Suppl 6():S14-24. PubMed ID: 25213870
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pathological spectrum in recurrences of glioblastoma multiforme.
    Marucci G; Fabbri PV; Morandi L; De Biase D; Di Oto E; Tallini G; Sturiale C; Franceschi E; Frezza GP; Foschini MP
    Pathologica; 2015 Mar; 107(1):1-8. PubMed ID: 26591624
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Detection of gene mutations and gene-gene fusions in circulating cell-free DNA of glioblastoma patients: an avenue for clinically relevant diagnostic analysis.
    Palande V; Siegal T; Detroja R; Gorohovski A; Glass R; Flueh C; Kanner AA; Laviv Y; Har-Nof S; Levy-Barda A; Viviana Karpuj M; Kurtz M; Perez S; Raviv Shay D; Frenkel-Morgenstern M
    Mol Oncol; 2022 May; 16(10):2098-2114. PubMed ID: 34875133
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.